Advances in Immunotherapy for Type 1 Diabetes
DOI:
https://doi.org/10.54097/e7mf5w82Keywords:
Type 1 diabetes, immunotherapy, monoclonal antibody.Abstract
Type 1 diabetes mellitus (T1D) is a common autoimmune disease. Global incidence is on the rise, and traditional insulin injection therapy cannot cure it. With the in-depth study of the pathogenesis of T1D and the progress of medical technology, a large number of innovative therapies are emerging. As one of them, the core of immunotherapy is to regulate the immune system, inhibit autoimmune response, and protect islet β cells. This article reviews the latest research progress of immunotherapy for T1D. Stem cell islet transplantation is relatively safe and effective but still has the risk of rejection. Monoclonal antibodies are effective but cannot be maintained for a long time. Vaccines are relatively simple, but the mechanism is still unclear. At the same time, combined with multiple clinical experimental cases, the development and limitations of immunotherapy at this stage are described in detail, trying to find a new method to break the curse that T1D cannot be cured.
Downloads
References
[1] Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS (10th ed.). Brussels: International Diabetes Federation; 2021.
[2] DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes [J]. Lancet (London, England), 2018, 391 (10138): 2449–2462.
[3] Warshauer JT, Bluestone JA, Anderson MS. New Frontiers in the Treatment of Type 1 Diabetes [J]. Cell Metabolism, 2020, 31 (1): 46–61.
[4] Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes [J]. Endocrinology and Metabolism Clinics of North America, 2010, 39 (3): 481–497.
[5] Ogle GD, Gregory GA, Wang F, et al. The T1D Index: Implications of Initial Results, Data Limitations, and Future Development [J]. Curr Diab Rep, 2023, 23 (10): 277–291.
[6] Gillespie KM. Type 1 diabetes: pathogenesis and prevention [J]. CMAJ: Canadian Medical Association Journal, 2006, 175 (2): 165–170.
[7] American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021 [J]. Diabetes Care, 2021, 44 (Suppl 1): S15–S33.
[8] DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes [J]. Lancet (London, England), 2018, 391 (10138): 2449–2462.
[9] Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes [J]. Diabetic Medicine: A Journal of the British Diabetic Association, 2013, 30 (7): 803–817.
[10] Shields BM, Peters JL, Cooper C, et al. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature [J]. BMJ Open, 2015, 5 (11): e009088.
[11] Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges [J]. Cell Stem Cell, 2020, 27 (4): 523–531.
[12] D'Amour KA, Agulnick AD, Eliazer S, et al. Efficient differentiation of human embryonic stem cells to definitive endoderm [J]. Nature Biotechnology, 2005, 23 (12): 1534–1541.
[13] Guo T, Landsman L, Li N, Hebrok M. Factors expressed by murine embryonic pancreatic mesenchyme enhance generation of insulin-producing cells from hESCs [J]. Diabetes, 2013, 62 (5): 1581–1592.
[14] Rezania A, Bruin JE, Riedel MJ, et al. Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice [J]. Diabetes, 2012, 61 (8): 2016–2029.
[15] Wang S, Du Y, Zhang B, et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient [J]. Cell, 2024, 187 (22): 6152–6164.e18.
[16] Klein HE. VX-880 shows promise for insulin-glucose management in T1D in new data. AJMC, June 23, 2023.
[17] Ke Q, Kroger CJ, Clark M, Tisch RM. Evolving Antibody Therapies for the Treatment of Type 1 Diabetes [J]. Frontiers in Immunology, 2021, 11: 624568.
[18] Thakkar S, Chopra A, Nagendra L, et al. Teplizumab in Type 1 Diabetes Mellitus: An Updated Review [J]. TouchREVIEWS in Endocrinology, 2023, 19 (2): 22–30.
[19] Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes [J]. The New England Journal of Medicine, 2019, 381 (7): 603–613.
[20] Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial [J]. Lancet (London, England), 2011, 378 (9790): 487–497.
[21] Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial [J]. Diabetes, 2013, 62 (11): 3766–3774.
[22] Rachid O, Osman A, Abdi R, Haik Y. CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes [J]. Expert Opinion on Investigational Drugs, 2020, 29 (3): 221–236.
[23] Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment [J]. Diabetes Care, 2014, 37 (4): 1069–1075.
[24] Schloot NC, Cohen IR. DiaPep277® and immune intervention for treatment of type 1 diabetes [J]. Clinical Immunology (Orlando, Fla.), 2013, 149 (3): 307–316.
[25] Schloot NC, Meierhoff G, Lengyel C, et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1 [J]. Diabetes/Metabolism Research and Reviews, 2007, 23 (4): 276–285.
[26] Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus [J]. The New England Journal of Medicine, 2012, 366 (5): 433–442.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
